Mohammad Aslam, MD
Internal Medicine · East Meadow, NYNPI 1821197708
Payments from drug & device makers
Across 333 payments — averaging $52.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Boehringer Ingelheim$2K
- Angiodynamics, Inc.$2K
- Novo Nordisk$2K
- GSK$1K
- Lilly USA, LLC$944
- plus $6K from 26 others
What the payments were for
- Travel & lodging$1,75610%
- Food & beverage$15,76990%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 61 | $3,585 |
| Boehringer Ingelheim | 25 | $1,858 |
| Angiodynamics, Inc. | 6 | $1,756 |
| Novo Nordisk | 25 | $1,501 |
| GSK | 16 | $1,417 |
| Lilly USA, LLC | 31 | $944 |
| Bayer | 27 | $682 |
| Pfizer | 26 | $646 |
| Abbott | 7 | $615 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $469 |
| Amarin Pharma, Inc. | 18 | $469 |
| Johnson & Johnson | 8 | $456 |
| Merck | 16 | $403 |
| Phathom Pharmaceuticals, Inc. | 7 | $399 |
| AbbVie(2 entities) | 10 | $391 |
| Insmed, Inc. | 2 | $250 |
| Actelion Pharmaceuticals US, Inc. | 2 | $247 |
| Sanofi-aventis U.S. LLC | 6 | $208 |
| Amgen | 5 | $196 |
| Global Blood Therapeutics, Inc. | 8 | $150 |
| Intuity Medical Inc | 1 | $134 |
| Lexicon Pharmaceuticals, Inc. | 1 | $125 |
| Neurocrine Biosciences, Inc. | 1 | $125 |
| Novartis | 6 | $116 |
| Mallinckrodt Hospital Products Inc. | 1 | $115 |
| Exact Sciences | 4 | $85 |
| Renalytix AI, Inc. | 2 | $45 |
| Shield Therapeutics Inc | 2 | $40 |
| Ultragenyx Pharmaceutical Inc. | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 1 | $22 |
| Sanofi | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,526 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 99 | $188,294 |
| JardianceEmpagliflozin | 130 | $132,055 |
| JanuviaSitagliptin Phosphate | 109 | $115,928 |
| FarxigaDapagliflozin Propanediol | 98 | $95,405 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 44 | $64,798 |
| TrulicityDulaglutide | 60 | $64,702 |
| EliquisApixaban | 45 | $46,639 |
| JanumetSitagliptin Phos/Metformin Hcl | 41 | $39,432 |
| RybelsusSemaglutide | 27 | $33,424 |
| UbrelvyUbrogepant | 18 | $31,232 |
| Diclofenac Sodium | 55 | $30,118 |
| Metformin Er GastricMetformin Hcl | 21 | $29,978 |
| XareltoRivaroxaban | 27 | $28,872 |
| Tresiba Flextouch U-100Insulin Degludec | 46 | $27,173 |
| LinzessLinaclotide | 42 | $25,481 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,501 | $221,718126 claims |
| MerckJanuvia, Janumet, Janumet Xr, Steglatro | $403 | $171,797178 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $1,858 | $141,119142 claims |
| AstraZenecaFarxiga, Symbicort | $3,585 | $102,649121 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $944 | $89,33884 claims |
| AbbVieUbrelvy, Linzess, Qulipta | $391 | $67,52471 claims |
| PfizerEliquis | $646 | $46,63945 claims |
| Johnson & JohnsonXarelto | $456 | $28,87227 claims |
| GSKTrelegy Ellipta | $1,417 | $23,01733 claims |
| NovartisEntresto | $116 | $15,37815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in East Meadow
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.